This page collects substantive developments in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), including new medical research, FDA and drug-safety actions, burn-care developments, and legal developments. It is updated as significant news is published.
For background on SJS/TEN and the records that matter when a medication reaction is investigated, see our SJS/TEN resource library.
2026 Updates
- FDA Adds Lamotrigine–HLA-B*15:02 Association to Pharmacogenetic Table: What It Means for SJS/TEN
- Antiseizure Drugs and SJS/TEN: New 2026 Research
- SJS/TEN Can Cause Long-Term Damage Beyond the Skin: What a New 2026 Systematic Review Shows
- Massachusetts Appeals Court Affirms SJS Verdict in Lamictal Dosing Case
- Ceftriaxone and SJS/TEN: New 2026 Study Suggests Risk May Differ Across Beta-Lactam Antibiotics
- NIH Launches First U.S. Research Consortium Focused on SJS/TEN and Other Severe Drug Reactions
- Could Cancer Immunotherapy Change SJS/TEN Risk From Other Drugs? A New Moxifloxacin Signal
- Long-Term Eye Damage After SJS: New Study Identifies Predictors of Vision Loss and Surgery